-
Product Insights
NewPrimary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024
Empower your strategies with our Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and...
-
Product Insights
NewSecondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
NewAnal Cancer – Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewLeukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024
Empower your strategies with our Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024 report and make more profitable business decisions. Leukocyte disorders, also known as white blood cell disorders, encompass a range of conditions that involve abnormalities in the production, function, or levels of white blood cells (leukocytes). White blood cells play a crucial role in the immune system, defending the body against infections, diseases, and foreign invaders. The Leukocyte Disorders (White Blood Cell Disorders) drugs in development...
-
Product Insights
NewRelapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024
Empower your strategies with our Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024 report and make more profitable business decisions. Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can...
-
Product Insights
NewUveal Melanoma – Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...
-
Product Insights
NewRadiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2024
Empower your strategies with our Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Radiation toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of ionizing radiation over a very short period of time (usually a matter of minutes). The root cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from...
-
Product Insights
NewHepatitis C – Drugs In Development, 2024
Empower your strategies with our Hepatitis C – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of...
-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...